NCT01637168

Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders

Clinical Phase III, Randomized, Double-blind, Prospective Study, for Efficacy and Safety Evaluation of Panax Ginseng + Associations Compared to Ginkgo Biloba in Symptomatic Cognitive Function Disorder Treatment.

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: EMS · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of two different drugs in the treatment of patients diagnosed with memory difficulties and a decline in cognitive function. This is a parallel distribution: a group of patients will be treated with a combination Panax Ginseng + Ginkgo Biloba + multivitamin + Polyminerals (EMS), and another group with Ginkgo Biloba (Tebonin ®).

Detailed description

STUDY DESIGN: * multicenter, phase III, double-blind, randomized entry of patients, prospective and comparative * The duration of the study: 60 days * 3 visits (days 1, 30 and 60) * Evaluate the effectiveness of the association * Evaluate the safety of the combination * Adverse events evaluation

Conditions

• Memory Deficit

Interventions

Type	Name	Description
DRUG	Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin	A tablet, 2 times daily (12/12 hours).
DRUG	Ginkgo Biloba (Tebonin®)	A tablet, 2 times daily (12/12 hours).

Timeline

• First posted: 2012-07-11
• Last updated: 2021-02-24

Locations

1 site across 1 country: Brazil